- Home
- CNEY vs SXTP Comparison
CNEY vs SXTP Comparison
Compare CNEY & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNEY | SXTP |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 3.6M |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CNEY | SXTP |
|---|---|---|
| Price | $0.50 | $0.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.70 |
| AVG Volume (30 Days) | ★ 310.8K | 135.7K |
| Earning Date | 02-17-2027 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,005,471.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.49 |
| 52 Week Low | $0.31 | $0.34 |
| 52 Week High | $2.63 | $8.62 |
Technical Indicators
Market Signals| Indicator | CNEY | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 37.33 | 37.97 |
| Support Level | $0.49 | $0.84 |
| Resistance Level | $0.62 | $1.66 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 19.35 | 0.14 |
Price Performance
Historical ComparisonAbout CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.